GlycoVaxyn Finalizes Deal to Fund Bioconjugation Program
By Nuala Moran
Friday, December 28, 2012
After landing the all-important validation of a deal with GlaxoSmithKline Biologicals (GSK) in December, GlycoVaxyn AG is expecting to finalize an agreement to fund development of its lead in-house program and seal further collaborations around its conjugated vaccine technology platform in 2013.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.